Straumann Announces Regenerative Portfolio Product Updates at Key U.S. Dental Meeting
· First Straumann AlloGraft now available through agreement with LifeNet Health®
· FDA approval supports new indication of Emdogain regenerative material for use with autograft, allograft, bone derived xenograft, ß-Tricalcium phosphate, and bioactive glass during bone graft procedures
· Straumann introduces new developments at the American Academy of Periodontology 95th Annual Meeting at Booth # 801 this week in Boston
BOSTON (American Academy of Periodontology (AAP) 95th Annual Meeting, Booth # 801) –September 12, 2009 – Straumann, a leader in restorative, replacement and regenerative dentistry, today announced two new developments to its regenerative product line: the addition of Straumann AlloGraft, the company’s first allograft product for bone regeneration, and the FDA approval of a new indication for Emdogain®, the company’s treatment for periodontal regeneration. With these announcements, Straumann expands its regenerative product portfolio to provide solutions for the various regenerative treatment situations a clinician can encounter – from root to tooth.
Straumann AlloGraft
Straumann has formed a partnership with LifeNet Health®, a leading Organ Procurement Organization (OPO) and one of the largest alloGraft bio-implant providers in the country, to offer its first Allograft product—Straumann AlloGraft.
Now Straumann offers both allograft and fully synthetic bone graft substitutes for bone regeneration procedures. Often dental implant placement is not possible because the patient lacks adequate bone volume to support an implant, causing practitioners to build up bone mass before placing an implant. Allograft and synthetic bone augmentation material re-establish bone dimension enabling the placement of dental implants in sites previously unsuitable for implant procedures.
Straumann AlloGraft eliminates the need for patients to donate bone to themselves, reducing the risk of additional complications associated with multiple surgical sites. Straumann AlloGraft undergoes LifeNet Health’s proprietary and patented Allowash XG® - the industry standard for allograft processing. LifeNet has distributed over two million allografts since 1995 without a single recorded infection transmission and has the longest continuous certification in the industry from the American Association of Tissue Banks.
New Indication for Straumann Emdogain
Additionally, Straumann has received FDA approval of a new indication of Emdogain, the company’s flagship regenerative product re-introduced to the market last year. Emdogain can now be used with a variety of bone graft materials, including autograft, allograft, bone-derived xenograft, beta-TCP or bioactive glass in wide defects or where additional soft tissue support is needed. This expanded use of Emdogain is supported by a consensus paper published by the European Federation of Periodontists, which concluded that of the treatment modalities researched only Emdogain alone or in combination with a bone graft material had substantial published evidence. Straumann Emdogain is a resorbable, injectable material that aids in the body’s natural ability to regenerate the tissues (cementum, alveolar bone, and periodontal ligament) responsible for tooth attachment when damaged by various forms of periodontal disease.
“With these new regenerative offerings, Straumann continues its commitment to providing dental professionals in the U.S. a range of treatment options as part of a comprehensive portfolio of products for replacement, restorative and regenerative dentistry,” said Martin Dymek, Regional Head North America. “The addition of Straumann AlloGraft and the new indication for Emdogain promotes choice and predictability for clinicians. Straumann’s commitment to produce quality esthetic and reliable results is aimed at producing higher patient satisfaction and ultimately, greater confidence for clinicians.”
Straumann will introduce both offerings at the American Academy of Periodontology 95th Annual Meeting (AAP), held this week in Boston. At the conference, Straumann Emdogain will also be featured in a presentation that outlines the effectiveness of coronally advanced flaps with the use of Emdogain® in the treatment of recession defects. This clinically-oriented lecture will blend diagnostic guidelines and step-by-step techniques to provide a well-rounded understanding regarding this treatment option and when it is indicated. Dr. Michael McGuire, DDS will lead the presentation at the Straumann Corporate Forum in Ballroom 210A.
About Straumann
Headquartered in Basel, Switzerland, the Straumann Group (SWX: STMN) is a global leader in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2200 people worldwide and its products and services are available in more than 60 countries through its broad network of distribution subsidiaries and partners.